Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Äèñêóññèîííûå ôîðóìû > Ðàçíîå

Ðàçíîå Ëþáûå ñîîáùåíèÿ íà ìåäèöèíñêèå òåìû, ïî êîòîðûì íåò îòäåëüíûõ ôîðóìîâ. Ôîðóì: ×àñòíàÿ ïðàêòèêà.

Çàêðûòàÿ òåìà
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1531  
Ñòàðûé 21.01.2004, 14:00
Àâàòàð äëÿ keldysh_zlobnyi
keldysh_zlobnyi keldysh_zlobnyi âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.01.2004
Ñîîáùåíèé: 14
keldysh_zlobnyi î ðåïóòàöèè ýòîãî ó÷àñòíèêà íåëüçÿ ñêàçàòü íè÷åãî îïðåäåëåííîãî
Ýòî âûäóìêà ãðà÷à
Îí ïîõîæ áûë íà âðà÷à.
  #1532  
Ñòàðûé 21.01.2004, 14:18
Àâàòàð äëÿ keldysh_zlobnyi
keldysh_zlobnyi keldysh_zlobnyi âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 19.01.2004
Ñîîáùåíèé: 14
keldysh_zlobnyi î ðåïóòàöèè ýòîãî ó÷àñòíèêà íåëüçÿ ñêàçàòü íè÷åãî îïðåäåëåííîãî
Îäíàêî ñòîðîííèêè òðàäèöèîííîé ìåäèöèíû äîëæíû ñåáå ñêàçàòü:"Ðåáÿòà äàâàéòå áûòü ñêðîìíåå. Ìû íå ìîæåì â íàñòîÿùåå âðåìÿ ïîáåäèòü âñå áîëåçíè. Ìû òîëüêî ñ íèìè áîðåìñÿ.... ñ ïåðåìåííûì óñïåõîì. Âîéñêî íàøå äîâîëüíî-òàêè ðàçðîçíåííî è íå âñåãäà âîîðóæåíî. È áûâàåò òàê, ÷òî ëåâàÿ ðóêà íå çíàåò, ÷òî äåëàåò ïðàâàÿ. Íå âñå ìû ðûöàðè áåç ñòðàõà è óïðåêà. Íåêîòîðûå èç íàñ âîþþò ñòðàõà ðàäè èóäåéñêà, íåêîòîðûå äâèæèìû æàæäîé ñëàâû, íàæèâû è äðóãèìè ïîðîêàìè, à íåêîòîðûå ïðîñòî ñëåïû è æèâóò äîãìàòîì. Ãëàâíîå, ÷òî íàñ äîëæíî îáúåäèíÿòü ýòî íå êîíãðåññû òàêîãî-òî ñîçûâà è ñèìïîçèóìû, à ïðèíöèï "Íå íàâðåäè" è âåðà â óñïåõ.
  #1533  
Ñòàðûé 22.01.2004, 17:58
Gromoboy Gromoboy âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.05.2003
Ñîîáùåíèé: 237
Gromoboy
Öèòàòà:
Îïóáëèêîâàíî: Aminazinka
à Âû íå â êóðñå ñëó÷àéíî, òåõíîëîãèè èçãîòîâëåíèÿ ãîìåîïàòè÷åñêèõ ñðåäñòâ? À â èçëîæåíèè òîâ. Ãàíåìàíà? ß-òî â êóðñå, ïåðâîèñòî÷íèê ÷èòàëà...È ïîïðîáóéòå ìíå äîêàçàòü, ÷òî ãîìåîïàòèÿ - íå ïñèõîòåðàïèÿ ñ øèðî÷àéøèì è äîñòàòî÷íî ïðèáûëüíûì ïðèìåíåíèåì ïëàöåáî...
Íó, ÷òåíèå íå ýêâèâàëåíòíî ïîíèìàíèþ. Ñåäàÿ, êàê ìèð, èñòèíà, ê-ðóþ ïðèõîäèòñÿ íàïîìèíàòü â ýííûé ðàç. À äîêàçûâàòü ÷òî-ëèáî òàêèì êàê Âû - íàïðàñíàÿ òðàòà õîðîøåãî âðåìåíè.

âñå ìû íåìíîæêî ëîøàäè...

Çàâèäíàÿ ñàìîêðèòèêà (ÿ. íàïðèìåð , òàê íå ñ÷èòàþ). Òîëüêî ïîçâîëüòå ïîèíòåðåñîâàòüñÿ - ýòî Âû î ôåíîòèïå èëè îá èíòåëëåêòå?
  #1534  
Ñòàðûé 23.01.2004, 15:49
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïîïóëÿðíàÿ ýõèíàöåÿ íå ëå÷èò, à ëèøü âûçûâàåò àëëåðãèþ

Ó÷åíûå àìåðèêàíñêîãî Óíèâåðñèòåòà äåòñêîãî öåíòðà Äæîðäæà Âàøèíãòîíà (University of Washington's Child Health Institute) óñòàíîâèëè, ÷òî ïîïóëÿðíûå ñðåäñòâà îò ïðîñòóäû íà îñíîâå ýõèíàöåè íå ïðèíîñÿò ïîëüçû, ïåðåäàåò Associated Press. Îáúåì ïðîäàæ òàêèõ ïðåïàðàòîâ â ÑØÀ äîñòèãàåò 300 ìèëëèîíîâ äîëëàðîâ â ãîä.

×òî êàñàåòñÿ ïðîôèëàêòèêè ïðîñòóäíûõ çàáîëåâàíèé, òî íåáîëüøîé ýôôåêò ýõèíàöåè, êîòîðûé íàáëþäàëè ó÷åíûå, ìîæåò îáúÿñíÿòüñÿ ñòàòèñòè÷åñêîé ïîãðåøíîñòüþ. Ïðè ýòîì èññëåäîâàòåëè äîêàçàëè, ÷òî ýõèíàöåÿ ìîæåò âûçâàòü àëëåðãèþ.

Êàê ñîîáùèë ðóêîâîäèòåëü èññëåäîâàíèÿ Äæåéìñ Òåéëîð (James Taylor), ñðåäè äâóõ ãðóïï äåòåé, êîòîðûå â ðàìêàõ ýêñïåðèìåíòà ïðèíèìàëè ýõèíàöåþ è ïëàöåáî, íå áûëî íèêàêèõ ðàçëè÷èé íè â ñðîêàõ âûçäîðîâëåíèÿ, íè â òÿæåñòè çàáîëåâàíèÿ, íè â åãî ïðîÿâëåíèÿõ.

Ïðè ýòîì ó÷åíûå íå íàçûâàþò ýõèíàöåþ îïàñíîé - âñå àëëåðãè÷åñêèå ðåàêöèè ïðîøëè ñàìîñòîÿòåëüíî, íå ïîòðåáîâàâ ìåäèêàìåíòîçíîãî ëå÷åíèÿ.

Èç ïðåïàðàòîâ íà îñíîâå ýõèíàöåè â Ðîññèè ïðîäàþòñÿ â îñíîâíîì ðàñòèòåëüíûå èììóíîñòèìóëÿòîðû.

Ãîìåîïàòèÿ ìîæåò ñäåëàòü ðàê ñìåðòåëüíûì

Êàê âûÿñíèëè áðèòàíñêèå ó÷åíûå, ïîïóëÿðíûå ïðåïàðàòû íà îñíîâå òðàâ ìîãóò ñâåñòè íà íåò ýôôåêò îò ëå÷åíèÿ ðàêà, ñîîáùàåòñÿ íà âåá-ñàéòå áðèòàíñêîé ãàçåòû Guardian.

Ïîïóëÿðíûå íàðîäíûå ñðåäñòâà èëè ïèùåâûå äîáàâêè çà÷àñòóþ âñòóïàþò âî âçàèìîäåéñòâèå ñ ëåêàðñòâàìè, êîòîðûå âûïèñûâàþò îíêîëîãè. Òàê, íàïðèìåð, ÷åñíîê èëè ïå÷åíü òðåñêè çíà÷èòåëüíî ðàçæèæàþò êðîâü, çâåðîáîé èçìåíÿåò äåéñòâèå ãîðìîíàëüíûõ ëåêàðñòâ, àíòèáèîòèêîâ è õèìèîòåðàïèè. À ýõèíàöåÿ, êîòîðóþ ïðèìåíÿþò äëÿ ïðîôèëàêòèêè ïðîñòóäû è ãðèïïà, äåëàåò ëå÷åíèå ðàêà êðîâè áåñïîëåçíûì.

Ëåêàðñòâà íà îñíîâå òðàâ ïðèíèìàþò áîëüøå ïîëîâèíû îíêîëîãè÷åñêèõ áîëüíûõ. Ïðè÷åì, êàê ïðàâèëî ïàöèåíòû íå ñîâåòóþòñÿ ñî ñâîèì ëå÷àùèì âðà÷îì.

Êàê îòìå÷àþò àâòîðû èññëåäîâàíèÿ, îïàñíîå ïðåäñòàâëåíèå î òîì, ÷òî ãîìåîïàòèÿ àáñîëþòíî áåçâðåäíà, åñòü è ó âðà÷åé, è ó ïàöèåíòîâ. Îäíàêî íàðîäíàÿ ìåäèöèíà íå ñòîëüêî áåçîïàñíà, ñêîëüêî íìàëî èçó÷åíà.

×óäî-íàñòîéêè ïîâûøàþò ðèñê êðîâîòå÷åíèÿ ïðè îïåðàöèè


Åñëè â òå÷åíèå ïîñëåäíèõ äâóõ íåäåëü ïåðåä îïåðàöèåé ïàöèåíò ïðèíèìàë ïðåïàðàòû ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ, â ðàáîòå õèðóðãà ìîãóò âîçíèêíóòü íåîæèäàííûå òðóäíîñòè: â ýòîé ñèòóàöèè íåðåäêî íàáëþäàåòñÿ çàìåäëåíèå ñâåðòûâàíèÿ êðîâè è ñêëîííîñòü ê êðîâîòå÷åíèÿì. Êàê ñîîáùàåò àãåíòñòâî CNN, ïðåçèäåíò Àìåðèêàíñêîãî îáùåñòâà àíåñòåçèîëîãîâ Äæîí Íèëò îáðàòèë âíèìàíèå ñïåöèàëèñòîâ íà ýòó ïðîáëåìó.

Íàó÷íûå èññëåäîâàíèÿ ýòîãî âîïðîñà åùå âïåðåäè.  íàñòîÿùèé ìîìåíò, ãîâîðÿ îá îïàñíîñòè, ñâÿçàííîé ñ øèðîêî ðåêëàìèðóåìûìè è äîñòóïíûìè áåç ðåöåïòà ïðåïàðàòàìè, âðà÷è áîëüøå îïèðàþòñÿ íà ñâîè íàáëþäåíèÿ è îïûò. Ïî ìíåíèþ Íèëòà, ïåðåä îïåðàöèåé àíåñòåçèîëîã äîëæåí ïîèíòåðåñîâàòüñÿ íå òîëüêî òåì, êàêèå ëåêàðñòâåííûå ïðåïàðàòû ïðèíèìàåò ïàöèåíò, íî è òåì, íå áàëóåòñÿ ëè îí ÷óäî-íàñòîéêàìè íà ýêçîòè÷åñêèõ òðàâàõ.

Âðà÷è îòìå÷àþò, ÷òî ðàñïðîñòðàíåííûå ïðåïàðàòû íà îñíîâå ãèíãêî áèëîáà, ýôåäðû èëè ÷åñíîêà ìîãóò îêàçûâàòü íåáëàãîïðèÿòíîå âëèÿíèå íà êðîâåíîñíóþ ñèñòåìó, à âàëåðèàíà è êàâà-êàâà óñèëèâàþò äåéñòâèå àíåñòåòèêîâ è çàòðóäíÿþò ïðîáóæäåíèå ïîñëå íàðêîçà. Äëÿ òîãî, ÷òîáû ïðåäóïðåäèòü âðà÷åé è ïàöèåíòîâ î ïîòåíöèàëüíîé îïàñíîñòè áåçîáèäíûõ íà ïåðâûé âçãëÿä íàñòîåê è îòâàðîâ, Àìåðèêàíñêîå îáùåñòâî àíåñòåçèîëîãîâ âûïóñòèëî èíôîðìàöèîííóþ áðîøþðó.

Èñòî÷íèê: Mednovosti
  #1535  
Ñòàðûé 23.01.2004, 17:25
Àâàòàð äëÿ Aminazinka
Aminazinka Aminazinka âíå ôîðóìà
Ìîë÷àëèâîå ïðèâèäåíèå
      
 
Ðåãèñòðàöèÿ: 25.12.2003
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 19,908
Ïîáëàãîäàðèëè 620 ðàç(à) çà 557 ñîîáùåíèé
Aminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAminazinka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ß è íå óäèâëÿþñü, áåçìåðíî äîðîãîé Gromoboy, ÷òî Âû òàê íå ñ÷èòàåòå...ñ÷èòàòü òîæå ó÷èòüñÿ íàäî...
__________________
Lead, follow, or get out of the way. — Thomas Paine
  #1536  
Ñòàðûé 23.01.2004, 18:35
homeo homeo âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.09.2001
Ãîðîä: Ðîññèÿ, Êðàñíîäàð
Ñîîáùåíèé: 14
homeo ýòîò ó÷àñòíèê èìååò ïëîõóþ ðåïóòàöèþ íà ôîðóìå
×òî êàñàåòñÿ ñâÿçè ãîìåîïàòèè ïñèõîòåðàïèè - òî î êàêîì âíóøåíèè ìîæåò èäòè ðå÷ü ïðè ãîìåîïàòè÷åñêîì ëå÷åíèè íàïðèìåð ðåáåíêà äî ãîäà ñ áðîíõèàëüíîé àñòîìîé èëè ýêçåìîé. Êîíå÷íî â ðàáîòå ëþáîãî âðà÷à ïðèñóòñòâóåò ýëëåìåíò ïñèõîëîãè÷åñêîãî âîçäåéñòâèÿ. Åñëè âðà÷ óâåðåí âñåáå, ìîæåò ñïðîãíîçèðîâàòü ïðîöåññ èçëå÷åíèÿ, åñëè îí ïðèâåòëèâ, îïòèìèñòè÷åí, òî êîíå÷íî ïàöèåíòó ëåã÷÷å ñïðàâèòñÿ ñî ñâîèìè ñòðàõàìè, íåäîâåðèåì, ëåã÷å ïðîòèâîñòîÿòü ñêåïñèñó çíàêîìûõ âðà÷åé, ðîäñòâåííèêîâ ïî ïîâîäó ãîìåîïàòè÷åñêîãî ëå÷åíèÿ.
Ïî ïîâîäó áåçâðåäíîñòè ãîìåîïàòè÷åñêîãî ëå÷åíèÿ - ýòî ìèô, êîòîðûé ðàñïðîñòðàíÿþò ïðîèçâîäèòåëè ãîì. êîìïëåêñîâ. Ýòî èõ áèçíåñ è êîíå÷íî îíè íàíîñÿò áîëüøîé âðåä ãîìåîïàòèè.
Îñíîâíîå ïðàâèëî ãîìåîïàòèè - îäíîìó ïàöèåíòó îäèí ïðåïàðàò, âñå îñòàëüíîå ãîìåîïàòè÷åñêîå øàðëàòàíñòâî.
Ïðèìåíåíèå ýõèíàöåè è ãîì.êîìïëåêñîâ äëÿ ïðîôèëàêòèêè ïðîñòóäíûõ çàáîëåâàíèé ýòî ïðîñòî îáìàí.
Ñîâåðøåííî ïðàâèëüíî áûëî îòìå÷åíî, ÷òî ïðèìåíåíèå òðàâ, ïèùåâûõ äîáàâîê, ãîìåîïàòè÷åñêèõ êîìïëåêñîâ, ìîæåò âûçâàòü èçìåíåíèÿ â îðãàíèçìå.
Îäèí ïðèìåð: âðà÷ ãîìåîïàò ñ ïåðåëîìîì ðóêè, ðåøèëà ñåáå ïîìî÷ü. Äëÿ óëó÷øåíèÿ ñðàñòàíèÿ îáëîìêîâ íà÷àëà ïðèíèìàòü
ãîìåîïàòè÷åñêèé ïðåïàðàò. Ñðàñòàíèå êîñòåé ïðîèçîøëî î÷åíü áûñòî, íî îíà ïðîäîëæàëà ïðèíèìàòü ïðåïàðàò, â ðåçóëüòàòå ÷åãî ïðîèçîøëî èçëèøíåå ðàçðàñòàíèå êîñòíîé òêàíè - âîçíèê âîïðîñ î ïîâòîðíîé îïåðàöèè, ÷òîáû óäàëèòü ýòè ðàçðàñòàíèÿ. Ýòî áûë âðà÷ ãîìåîïàò, à ÷òî ãîâîðèòü áåñêîíòðîëüíîì ïðèìåíåíèè ãîì.êîìïëåêñîâ ïàöèåíòàìè. Îøèáêà çàêëþ÷àëàñü â òîì, ÷òî ýòîò ïðåïàðàò èñïîëüçóåòñÿ òîëüêî ïðè çàìåäëåííîì ñðàñòàíèè êîñòåé è îïðåäåëåííîå âðåìÿ.
Òàê, ÷òî íå áûâàåò áåçîïàñíîé ãîìåîïàòèè, åñëè ïðåïàðàòà ïðèíèìàþòñÿ áåç íàçíà÷åíèÿ è êîíòðîëÿ êâàëèôèöèðîâàííîãî âðà÷à ãîìåîïàòà.
  #1537  
Ñòàðûé 23.01.2004, 18:52
Gromoboy Gromoboy âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.05.2003
Ñîîáùåíèé: 237
Gromoboy
Óâ. À Ñòîëÿðîâ!(homeo) Ïðîöèòèðîâàííàÿ ä-ðîì Âàäîì èíôîðìàöèÿ â ò.÷. ñîäåðæèò è ïðÿìóþ ëîæü, êàê ÿâñòâóåò èç îòðûâêà. ê-ðûé ÿ ïðèâåäó â ñëåäóþùåì ïîñòå. Àâòîðû ýòîé çàìåòêè íå çíàþò ðàçëè÷èÿ ìåæäó ãîìåîïàòèåé è ôèòîòåðàïèåé. Ìîæåò áûòü, åå íå çíàåò è ä-ð Âàä?
  #1538  
Ñòàðûé 23.01.2004, 18:55
Gromoboy Gromoboy âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.05.2003
Ñîîáùåíèé: 237
Gromoboy
íàãëàÿ ëîæü

Öèòàòà:
Îïóáëèêîâàíî: Dr. Vad

Ãîìåîïàòèÿ ìîæåò ñäåëàòü ðàê ñìåðòåëüíûì

Êàê âûÿñíèëè áðèòàíñêèå ó÷åíûå, ïîïóëÿðíûå ïðåïàðàòû íà îñíîâå òðàâ ìîãóò ñâåñòè íà íåò ýôôåêò îò ëå÷åíèÿ ðàêà, ñîîáùàåòñÿ íà âåá-ñàéòå áðèòàíñêîé ãàçåòû Guardian.

Ïîïóëÿðíûå íàðîäíûå ñðåäñòâà èëè ïèùåâûå äîáàâêè çà÷àñòóþ âñòóïàþò âî âçàèìîäåéñòâèå ñ ëåêàðñòâàìè, êîòîðûå âûïèñûâàþò îíêîëîãè. Òàê, íàïðèìåð, ÷åñíîê èëè ïå÷åíü òðåñêè çíà÷èòåëüíî ðàçæèæàþò êðîâü, çâåðîáîé èçìåíÿåò äåéñòâèå ãîðìîíàëüíûõ ëåêàðñòâ, àíòèáèîòèêîâ è õèìèîòåðàïèè. À ýõèíàöåÿ, êîòîðóþ ïðèìåíÿþò äëÿ ïðîôèëàêòèêè ïðîñòóäû è ãðèïïà, äåëàåò ëå÷åíèå ðàêà êðîâè áåñïîëåçíûì.
Ìíå áû î÷åíü õîòåëîñü, ÷òîáû àâòîðû äàííûõ îïóñîâ îçíàêîìèëèñü õîòÿ áû ñ èíñòèòóòñêèì êóðñîì ôàðìîêîëîãèè (ãíîçèè) è óçíàëè áû ðàçíèöó ìåæäó ïðåïàðàòàìè ôèòîòåðàïåâòè÷åñêèìè è ÃÎÌÅÎÏÀÒÈ×ÅÑÊÈÌÈ.
  #1539  
Ñòàðûé 23.01.2004, 19:40
vvd vvd âíå ôîðóìà
çàáàíåí
 
Ðåãèñòðàöèÿ: 24.12.2003
Ñîîáùåíèé: 75
vvd êàíäèäàò íà óäàëåíèå ñ ôîðóìà â ñâÿçè ñ ìíîãî÷èñëåííûìè îòðèöàòåëüíûìè îòçûâàìè
Äëÿ îðãàíèçìà ýõèíàöåÿ - êñåíîáèîòèê. Ïîýòîìó, íå áóäü îíà âðåäíà, îíà íèêîãäà áû íå ïðèìåíÿëàñü â ãîìåîïàòèè. Ïðèìåíåíèå ïîäîáíûõ òðàâ â íàðîäíîé è øêîëüíîé ìåäèöèíå - íè ÷òî èíîå, êàê ïðèìèòèâíàÿ ãîìåîïàòèÿ. È â àííîòàöèÿõ ê ïîäîáíûì ñíàäîáüÿì ÷àñòî ìîæíî ïðî÷åñòü "ìåõàíèçì ôàðìàêîëîãè÷åñêîãî äåéñòâèÿ íå âûÿñíåí". È íè îäèí èñêóññíûé òðàâíèê (â îòëè÷èå îò ñàìîëåêàðåé, èñêðåííå âåðóþùèõ â òî, ÷òî "íàòóðàëüíîå" áåçâðåäíî) íå èñïîâåäóåò ïðèíöèïà "÷åì áîëüøå - òåì ëó÷øå", à îïåðèðóåò ñòðîãî âûâåðåííûìè äîçàìè è ðåæèìàìè ïðèåìà.

Êîììåíòàðèè ê ñîîáùåíèþ:
E.E. Studentsov íå îäîáðèë(à):
  #1540  
Ñòàðûé 25.01.2004, 11:48
Sly Sly âíå ôîðóìà
çàáàíåí
 
Ðåãèñòðàöèÿ: 31.07.2003
Ñîîáùåíèé: 34
Sly
×òîáû Dr. Vad íåïîâàäíî áûëî!

Öèòàòà:
Îïóáëèêîâàíî: Dr. Vad
Ïîïóëÿðíàÿ ýõèíàöåÿ íå ëå÷èò, à ëèøü âûçûâàåò àëëåðãèþ

Èñòî÷íèê: Mednovosti
Ýòà ÷óøü óæå ïðîêîììåíòèðîâàíà çäåñü. Ñòûäíî, ä-ð Âàä.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
E.E. Studentsov íå îäîáðèë(à):
  #1541  
Ñòàðûé 25.01.2004, 23:00
Àâàòàð äëÿ Hard
Hard Hard âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.12.2002
Ãîðîä: Ìîñêâà - Los Angeles
Ñîîáùåíèé: 1,703
Ïîáëàãîäàðèëè 18 ðàç(à) çà 13 ñîîáùåíèé
Hard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåHard ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Re: íàãëàÿ ëîæü

Öèòàòà:
Îïóáëèêîâàíî: Gromoboy
Ìíå áû î÷åíü õîòåëîñü, ÷òîáû àâòîðû äàííûõ îïóñîâ îçíàêîìèëèñü õîòÿ áû ñ èíñòèòóòñêèì êóðñîì ôàðìîêîëîãèè (ãíîçèè) è óçíàëè áû ðàçíèöó ìåæäó ïðåïàðàòàìè ôèòîòåðàïåâòè÷åñêèìè è ÃÎÌÅÎÏÀÒÈ×ÅÑÊÈÌÈ.
Íó, ýòî ñîâñåì ïðîñòî: â ïðåïàðàòàõ ôèòîòåðàïåâòè÷åñêèõ ñîäåðæèòñÿ äåéòâóþùåå âåùåñòâî, à â ÃÎÌÅÎÏÀÒÈ×ÅÑÊÈÕ (ò.å. ïóñòîòåðàïåâòè÷åñêèõ) - ñîäåðæèòñÿ êóêèø.


Êñòàòè, à ÷òî, ä-ð. Äâîðÿí÷èêîâ, âûñòóïàþùèé òåïåðü ïîä íèêîì vvd, ñ÷èòàåò, ÷òî â ãîìåîïàòèè íå ïðèìåíÿþòñÿ âåùåñòâà, êîòîðûå ñàìè ïî ñåáå íå âðåäíû äëÿ îðãàíèçìà?

Êîììåíòàðèè ê ñîîáùåíèþ:
Naol îäîáðèë(à):
  #1542  
Ñòàðûé 26.01.2004, 13:07
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. SLy!

Öèòàòà: "×òîáû Dr. Vad íåïîâàäíî áûëî! ...Ñòûäíî, ä-ð Âàä."

Çà ÷òî ìíå äîëæíî áûòü ñòûäíî è íåïîâàäíî âïðåäü ñîâåðøàòü? Îïóáëèêîâàë ôðàãìåíò íîâîñòåé, Âû â îòâåò - ôðàãìåíò äð. ôîðóìà. Â÷åðà ãîâîðèëè/ïèñàëè "ÊÏÑÑ -íàø ðóëåâîé", ñåãîäíÿ ïèøóò - ÂÂÏ.
Êàê ãîâîðÿò â Îäåññå: "Åñëè âåðèòü âñåìó, ÷òî ïèøóò íà çàáîðå..." Ê ñîæàëåíèþ, áîëüøèíñòâî ìåäèíôî, ïóáëèêóåìîé äàæå â îòå÷åñòâåííûõ æóðíàëàõ, ïî ñîäåðæàíèþ íå îòëè÷àþòñÿ îò íàçàáîðíûõ. Êîãäà ìíå íóæíà ðåàëüíàÿ èíôî îòíîñèòåëüíî òåêóùåãî ïîëîæåíèÿ äåë â êàêîé-òî èç îáëàñòåé ìåäèöèíû, ïðèáåãàþ ê ïîìîùè êëèí.ðóêîâîäñòâ, íå ñòàðøå 10-ëåòíåé äàâíîñòè è èçäàííûõ íå íà ýòîé òåððèòîðèè.
  #1543  
Ñòàðûé 26.01.2004, 18:31
Sly Sly âíå ôîðóìà
çàáàíåí
 
Ðåãèñòðàöèÿ: 31.07.2003
Ñîîáùåíèé: 34
Sly
Dr. Vad, òî, ÷òî Âû îïóáëèêîâàëè - ôðàãìåíò íå íîâîñòåé, à îòêðîâåííîé ÷óøè, ê òîìó æå ÿâíî çàêàçíîé. À ïîñêîëüêó ýòî áûëî îïóáëèêîâàíî Âàìè áåç âñÿêèõ êîììåíòàðèåâ, äà åùå â òîïèêå, ãäå ò.í. íàó÷íûå âðà÷è êëåéìÿò øàðëàòàíñòâîì âñå, ÷òî ñàìè íå â ñîñòîÿíèè ïîíÿòü, òî òðóäíî îòäåëàòüñÿ îò ïîäîçðåíèÿ, ÷òî Âû íåóêëþæóþ ðàçâîäêó "ìåäíîâîñòè.ðó" ïðèíÿëè çà ÷èñòóþ ìîíåòó.
  #1544  
Ñòàðûé 27.01.2004, 15:08
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. SLY! Åäèíñòâåííîå íåñîîòâåòñòâèå, êîòîðîå íàáëþäàåòñÿ (è ñ êîòîðûì Âû î÷åâèäíî íàèáîëåå íå ñîãëàñíû) â äàííîì ñîîáùåíèè - ýòî óïîìèíàíèå ãîìåîïàòèè íàðàâíå ñ òðàâíûìè ëåêàðñòâàìè êàê ïîòåíöèàëüíîì ðèñêå ïðè ëå÷åíèè îïóõîëåé (ïðàâäà, èìåííî â ëå÷åíèè îïóõîëåé ãîìåîïàòè÷åñêèå óñïåõè íàèìåíåå çàìåòíû â çàðóáåæíûõ ïóáëèêàöèÿõ). Ïî îñòàëüíîé ÷àñòè âòîðîãî òîïèêà íå õîòèòå âèäåòü "ðàçâîäêè" îò îòå÷åñòâåííûõ ìåäíîâîñòåé - ïîçâîëüòå îçíàêîìèòü ñ îòðûâêàìè èç îðèãèíàëà ïóáëèêàöèè (íåîáõîäèìû íàâûêè ïîíèìàíèÿ ìåä. àíãëèéñêîãî):

British Journal of Cancer (2004) 90, 408-413.

Potential health risks of complementary alternative medicines in cancer patients

U Werneke1,2,8, J Earl3, C Seydel4, O Horn5, P Crichton6 and D Fannon7

1Homerton Hospital, East Wing, Department of Psychiatry, Homerton Row, London E9 6SR, UK

2Centre for the Economics in Mental Health, Institute of Psychiatry, De Crespigny Park, London SE5 8AJ, UK

3Pharmacy Department, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK

4Pharmacy Department, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK

5Academic Department of Psychological Medicine, King's College School of Medicine and Dentistry and Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK

6Department of Psychological Medicine, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK

7Maudsley Hospital & Division of Psychological Medicine, Institute of Psychiatry, Denmark Hill London SE5 8AZ, UK



Correspondence to: Dr U Werneke, Homerton Hospital, East Wing, Department of Psychiatry, Homerton Row, London E9 6SR, UK. E-mail: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

8Ursula Werneke has received a grant form Pfizer Ltd and honoraria and speaker fees from Ely Lilly Ltd, all unrelated to this particular study and unrelated to the topic of CAMs in general.

Received 27 August 2003; revised 13 November 2003; accepted 13 November 2003



Many cancer patients use complementary alternative medicines (CAMs) but may not be aware of the potential risks. There are no studies quantifying such risks, but there is some evidence of patient risk from case reports in the literature. A cross-sectional survey of patients attending the outpatient department at a specialist cancer centre was carried out to establish a pattern of herbal remedy or supplement use and to identify potential adverse side effects or drug interactions with conventional medicines. If potential risks were identified, a health warning was issued by a pharmacist. A total of 318 patients participated in the study. Of these, 164 (51.6%) took CAMs, and 133 different combinations were recorded. Of these, 10.4% only took herbal remedies, 42.1% only supplements and 47.6% a combination of both. In all, 18 (11.0%) reported supplements in higher than recommended doses. Health warnings were issued to 20 (12.2%) patients. Most warnings concerned echinacea in patients with lymphoma. Further warnings were issued for cod liver/fish oil, evening primrose oil, gingko, garlic, ginseng, kava kava and beta-carotene. In conclusion, medical practitioners need to be able to identify the potential risks of CAMs. Equally, patients should be encouraged to disclose their use. Also, more research is needed to quantify the actual health risks.

Keywords: complementary alternative medicines; herbal remedies; supplements; cancer; risks; echinacea



The use of complementary alternative medicines (CAM) is well documented (Ernst and Cassileth, 1999). These are either used on their own (alternative) or in addition to conventional medicine (complementary) (Zimmerman and Thompson, 2002). This is particularly common in patients suffering from chronic disorders such as cancers and their associated physical and psychological problems. Depending on the definition and inclusion criteria chosen, estimates range from 7 to 64% in the reported prevalence of CAM use in cancer patients (Ernst and Cassileth, 1998). More recent studies have reported an even higher prevalence of between 70 and 80% (Richardson et al, 2000; Bernstein and Grasso, 2001; Ashikaga et al, 2002). The nature of CAMs used, for example, vitamins and other supplements, herbal remedies, physical and psychological treatments, also varies greatly (Risberg et al, 1998; Richardson et al, 2000; Sparber et al, 2000; Bernstein and Grasso, 2001; Ashikaga et al, 2002).

Patients with chronic illnesses who seek alternative therapies are likely to use conventional medicine regularly and simultaneously. However, they may not always inform their doctor of the concomitant use of alternative medicine. For instance, a study of Eisenberg and co-workers in the US showed that 96% of alternative-medicine users also sought a conventional medicine provider for at least one medical condition. In all, 28% used alternative medicine for the same medical condition, and 72% did not inform their physician (Eisenberg et al, 1993; Kessler et al, 2001). The reasons for CAM use have been widely investigated. Patients often wish to combine conventional and CAM approaches to improve their quality of life, to counter side effects, to achieve a sense of control and to match their life style with their world view (Austin, 1998; Sparber et al, 2000; Kessler et al, 2001).

However, the use of CAM and especially of herbal remedies and supplements is not without problems. Unconventional cancer therapies such as Laetrile, Essiac and coenzyme Q10 may not be effective (Ernst and Cassileth, 1999). Furthermore, CAMs have potentially dangerous side effects and interactions with conventional treatments. For instance, garlic and cod liver oil have anticoagulant effects (Fugh-Berman, 2000), and remedies acting on the cytochrome P450 system such as St John's wort, may interact with hormones, antibiotics and chemotherapeutic agents (Izzo and Ernst, 2001).

Many reviews of the potential dangers have been published, but clinical accounts are mostly confined to individual case reports of adverse events (Ernst, 1998). The purpose of this survey was to prevent potential health risks, which CAM users might encounter. We aimed to establish the type, frequency and pattern of herbal medicine and supplement use in a sample of cancer patients and to identify and quantify the potential for adverse side effects or drug interactions with conventional medicines.
  #1545  
Ñòàðûé 27.01.2004, 15:11
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
...DISCUSSION

Our survey confirms that there is a high prevalence of herbal medicine and supplement use in cancer patients. A substantial proportion of patients used remedies that have the potential to cause serious adverse reactions or drug interactions. To our knowledge, this survey is the first attempt to identify these potential risks for an actual sample of cancer patients before adverse events have emerged. However, we do not know how these potential risks translate into actual events, and research is required to establish the frequency and seriousness of such side effects and drug interactions. As this study was based on voluntary participation and CAM users seemed to be more likely to participate, we may have overestimated CAM use. However, even if all nonparticipants did not use any form of alternative remedy, the proportion of CAM users would still be 33%. Nonparticipation did not affect the risk estimates, that is, the main area of interest in this study. It was also difficult to draw a clear line between remedies and supplements as these overlap and many patients took combinations.

Although most patients had discussed their use with a health-care professional, there remained a considerable potential for harmful effects. There may be different reasons for this. Medical practitioners may not have the expert knowledge required to deal with the large number of potential risks or may not have the time to do so in routine outpatient clinics. Also, patients may not accept their doctors' opinion and may argue that conventional cancer treatment can be equally toxic. Thus patients may require more education on the benefits of CAMs and their risk management. For instance, patients need to know that for some vitamins, effectiveness is only established when taken in fruit and vegetables but not as supplements (Moertel et al, 1985) or that effectiveness of supplements may be confined to specifically selected populations (Blot et al, 1993; Russell, 2000). They also need to know that supplements may be associated with adverse events including bleeding and liver failure (Palmer et al, 2003) or fail to work, for example, high dose vitamin C (Creagan et al, 1979). Only recently, the UK Food Standards Agency has reduced the safe upper limit for many supplements (Food Standards Agency, 2003). Also, the potential for CAM to interact with drugs given during diagnostic procedures or radiotherapy needs to be recognised. For instance, kelp can interact with contrast agents containing iodine, as used in bone and thyroid scanning (Eliason, 1998). Antioxidants binding free radicals or remedies increasing photosensitivity may interfere with radiotherapy (Ernst, 1998).

Our survey highlights the importance for conventional health-care professionals to discuss CAM use with their patients. Clinicians need to be aware of CAM-induced side effects or interactions and identify hazards, advising patients accordingly and avoiding uncritical encouragement of potentially harmful use. Otherwise, prescribers may expose themselves to criticism and possibly litigation (Cohen and Eisenberg, 2002). Equally patients should be encouraged to disclose information about CAMs to health-care professionals. Such discussions need to be conducted sensitively in order to avoid alienating patients who may feel that they have not been taken seriously or have been criticised for using CAM. Also, given that about one-third of the remedies used had psychotropic effects, the question of whether CAM users have special psychological needs should be explored.

Also, research on CAMs and their interactions with conventional medicines needs to keep pace with the development of new cancer therapies. Although in randomised controlled trials the proportion of CAM users should be equal in each trial arm, the trial outcome could theoretically be influenced if a CAM specifically interacts with the trial agent but not with the control medication/placebo.

Doctors will need to devote time to discussing CAM use in outpatient clinics, although the complexities of side effects and interactions may require clinics that are run jointly with a local medicines information and toxicology services that provide access to and interpretation of herbal formularies, reference texts and web-based resources such as Natural Medicines Comprehensive Database (2003) (naturaldatabase.com) and Longwood Herbal Task Force ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]). Also, pharmacists have a key role in updating physicians and sharing important information gathered from patients with other health-care professionals (Klepser and Klepser, 1999). Service models need to be designed and tested to meet this challenge.
Çàêðûòàÿ òåìà



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 05:30.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.